Prognostic value of [18F]-fluoromethylcholine PET/CT Before Stereotactic Body Radiotherapy For Oligometastatic Prostate Cancer

Treating oligometastases detected by [18F]-fluoromethylcholine positron-emission tomography/computed tomography (PET/CT) with stereotactic body radiotherapy (SBRT) may postpone initiation of androgen-deprivation therapy, and possibly prolong progression-free survival (PFS). However, better prognostic factors are needed to improve patient selection. We investigated the predictive value of [18F]-fluoromethylcholine-PET/CT-derived parameters on PFS in oligometastatic prostate cancer patients treated with SBRT.

Source: International Journal of Radiation Oncology * Biology * Physics - February 13, 2018 Category: Radiology Authors: M.C.F. Cysouw, E.W. Bouman-Wammes, O.S. Hoekstra, A.J.M. van den Eertwegh, A.H.M. Piet, R.J.A. van Moorselaar, R. Boellaard, M. Dahele, D.E. Oprea-Lager Source Type: research